125 related articles for article (PubMed ID: 20082632)
1. Infliximab treatment in a patient with Crohn's disease on haemodialysis.
Kume K; Yamasaki M; Yoshikawa I; Harada M
Colorectal Dis; 2011 Mar; 13(3):341. PubMed ID: 20082632
[No Abstract] [Full Text] [Related]
2. Increased plasma ghrelin following infliximab in Crohn's disease.
Sung EZ; Da Silva NF; Goodyear S; McTernan PG; Sanger GJ; Nwokolo CU
Aliment Pharmacol Ther; 2009 Jan; 29(1):83-9. PubMed ID: 18793341
[TBL] [Abstract][Full Text] [Related]
3. Influence of immunogenicity on the long-term efficacy of infliximab in Crohn's disease.
Baert F; Noman M; Vermeire S; Van Assche G; D' Haens G; Carbonez A; Rutgeerts P
N Engl J Med; 2003 Feb; 348(7):601-8. PubMed ID: 12584368
[TBL] [Abstract][Full Text] [Related]
4. Infliximab and the bone in Crohn's disease.
Kunisaki R; Chaki O; Taguchi T; Sugiyama T; Sugita A
Aliment Pharmacol Ther; 2005 Mar; 21(6):789-90. PubMed ID: 15771766
[No Abstract] [Full Text] [Related]
5. [Infliximab in the treatment of Crohn's disease -- a practical approach. Infliximab and chronic Crohn's disease--Consensus statement of the Working Group on Chronic Inflammatory Crohn's Diseases of the OGGH].
Tilg H; Knoflach P; Petritsch W; Vogelsang H; Reinisch W;
Z Gastroenterol; 2004 Oct; 42(10):1256-63. PubMed ID: 15508068
[No Abstract] [Full Text] [Related]
6. [Indications and results of infliximab in Crohn's disease].
Karoui S; Boubaker J; Filali A
Tunis Med; 2004 Dec; 82(12):1057-63. PubMed ID: 15822505
[TBL] [Abstract][Full Text] [Related]
7. Infliximab in the management of the extra-intestinal manifestations of Crohn's disease.
Lawrance IC
J Gastroenterol Hepatol; 2004 Nov; 19(11):1332-3. PubMed ID: 15482549
[No Abstract] [Full Text] [Related]
8. Infliximab: lifetime use for maintenance is appropriate in Crohn's Disease. A BALANCING VIEW: lifetime channeling of infliximab for crohn's disease.
Hanauer SB
Am J Gastroenterol; 2005 Jul; 100(7):1438-9. PubMed ID: 15984961
[No Abstract] [Full Text] [Related]
9. Evidence for the clinical use of infliximab in Crohn's disease.
Turner SM; Probert CS
Rom J Gastroenterol; 2003 Mar; 12(1):2-5. PubMed ID: 12673372
[No Abstract] [Full Text] [Related]
10. Administration of infliximab in Crohn's disease does not deplete complement components C3 and C4.
Arnott ID; Shand A; Ghosh S
Am J Gastroenterol; 2000 Nov; 95(11):3326-7. PubMed ID: 11095380
[No Abstract] [Full Text] [Related]
11. A case of hereditary hemorrhagic telangiectasia associated with Crohn's disease successfully treated with infliximab.
Papa A; Felice C; Marzo M; Guidi L
Am J Gastroenterol; 2010 Aug; 105(8):1904. PubMed ID: 20686472
[No Abstract] [Full Text] [Related]
12. Complications of infliximab therapy in children and adolescents affected by Crohn's disease.
Diamanti A; Papadatou B; Knafelz D; Gambarara M; Ferretti F; Castro M
Am J Gastroenterol; 2003 Dec; 98(12):2812-3. PubMed ID: 14687847
[No Abstract] [Full Text] [Related]
13. The prevalence of malnutrition and the evolution of nutritional status in patients with moderate to severe forms of Crohn's disease treated with Infliximab.
Vadan R; Gheorghe LS; Constantinescu A; Gheorghe C
Clin Nutr; 2011 Feb; 30(1):86-91. PubMed ID: 20719413
[TBL] [Abstract][Full Text] [Related]
14. Infliximab (Remicade), a new biological treatment for Crohn's disease.
D'Haens GR
Ital J Gastroenterol Hepatol; 1999; 31(6):519-20. PubMed ID: 10575573
[TBL] [Abstract][Full Text] [Related]
15. [Treatment of Crohn's disease by infliximab. About 20 cases].
Serghini M; Karoui S; Meknini M; Matri S; Kallel L; Fekih M; Boubaker J; Filali A
Tunis Med; 2009 Sep; 87(9):579-82. PubMed ID: 20180377
[TBL] [Abstract][Full Text] [Related]
16. [Infliximab--practical guidelines for the treatment of Crohn's disease].
Bauerfeind P; Beglinger C; Beltinger J; Braegger C; Eigenmann F; Fried M; Guyot J; Hürlimann R; Michetti P; Seibold F; Straumann A
Rev Med Suisse; 2006 Jul; 2(74):1807-15. PubMed ID: 16927560
[TBL] [Abstract][Full Text] [Related]
17. The Dutch guidelines for treatment with infliximab for Crohn's disease.
Vermeire S
Neth J Med; 2006; 64(7):210-1. PubMed ID: 16929081
[No Abstract] [Full Text] [Related]
18. Clinical evolution of luminal and perianal Crohn's disease after inducing remission with infliximab: how long should patients be treated?
Domènech E; Hinojosa J; Nos P; Garcia-Planella E; Cabré E; Bernal I; Gassull MA
Aliment Pharmacol Ther; 2005 Dec; 22(11-12):1107-13. PubMed ID: 16305724
[TBL] [Abstract][Full Text] [Related]
19. Prolonged duration of response to infliximab in early but not late pediatric Crohn's disease.
Kugathasan S; Werlin SL; Martinez A; Rivera MT; Heikenen JB; Binion DG
Am J Gastroenterol; 2000 Nov; 95(11):3189-94. PubMed ID: 11095340
[TBL] [Abstract][Full Text] [Related]
20. The duration of effect of infliximab maintenance treatment in paediatric Crohn's disease is limited.
De Bie CI; Hummel TZ; Kindermann A; Kokke FT; Damen GM; Kneepkens CM; Van Rheenen PF; Schweizer JJ; Hoekstra JH; Norbruis OF; Tjon A Ten WE; Vreugdenhil AC; Deckers-Kocken JM; Gijsbers CF; Escher JC; De Ridder L
Aliment Pharmacol Ther; 2011 Jan; 33(2):243-50. PubMed ID: 21083595
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]